NurExone Biologic (TSXV:NRX) Dividends per Share : C$0.00 (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Dividends per Share?

NurExone Biologic's dividends per share for the three months ended in Sep. 2024 was C$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, NurExone Biologic's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

NurExone Biologic Dividends per Share Historical Data

The historical data trend for NurExone Biologic's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Dividends per Share Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dividends per Share

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Dividends per Share	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of NurExone Biologic's Dividends per Share

For the Biotechnology subindustry, NurExone Biologic's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Dividend Yield % falls into.

NurExone Biologic Dividends per Share Calculation

Dividends paid to per common share.

NurExone Biologic (TSXV:NRX) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

NurExone Biologic's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-0.027
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

NurExone Biologic Dividends per Share Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

NRXBF:USA J90:Germany

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

Executives

James Angus Wilson (bilkstys-) Richardson

10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines